There is no panel matching the key "Alert"
There is no panel matching the key "MicroAlert"

Cancer & Blood Disorders Clinical Trials

Gundersen Health System has about 100 research studies available for cancer patients at any given time.

With support from Gundersen Medical Foundation, the Cancer and Blood Disorders Center offers research studies through participation in regional and national cancer treatment cooperative groups. By sharing clinical research efforts and measuring collective results, treatments are advanced more rapidly than any institution can accomplish alone. Participation in these groups can shorten the time it takes for us to get new, more effective drugs on the market.

Sometimes patients are concerned that if they don't get the experimental therapy, they will only get a placebo. However, in cancer research, the patient will either get the standard treatment or the new experimental drug that has shown signs to be potentially better than the standard treatment. Not everyone will qualify for a cancer research study, but for those who do, it can offer new hope.

Brain/Central Nervous System Cancer

  • Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations (Suspended)
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NCCTG N0577: Phase III Randomized Study of Radiotherapy Alone Versus Radiotherapy With Concurrent and Adjuvant Temozolomide Versus Temozolomide Alone in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Glioma
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • WF 1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Breast Cancer

EARLY STAGE

Adjuvant

  • Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL)
  • A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
  • A221505: Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
  • CCTG.MA.39 Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)
  • NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
  • SWOG S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
  • WF-97116: A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Neoadjuvant

  • Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy (SUSPENDED)
  • ECOG EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

ADVANCED/METASTATIC

  • A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (TEMPORARILY CLOSED TO ACCRUAL 9/13/2019)
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Gastrointestinal Cancer

COLORECTAL

  • A021502: Randomized Trial of Standard Chemotherapy
    Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
  • EAQ162CD: Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609:(Suspended 4/20/18) "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification (Suspended 5/16/2019)

HEPATOCELLULAR

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

GASTRIC

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

ESOPHAGEAL

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

PANCREATIC

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

CHOLANGIOCARCINOMA

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1815 - A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Genitourinary Cancer

BLADDER

  • A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation
  • A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

PROSTATE

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-GU005: Phase II IGRT And SRBT Vs IGRT And Hypofractionated IMRT For Localised Intermediate Risk Prostate Cancer
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • WF-1802 - Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

RENAL CELL

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Gynecological Cancer

CERVICAL

  • GOG 0263: Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

ENDOMETRIAL

  • GOG 0238: Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
  • Lunchbox: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC004 - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
  • NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) (SUSPENDED)
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Head and Neck Cancer

  • ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
  • NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin (SUSPENDED 06/25/2018)
  • NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • RTOG 1216: Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer (SUSPENDED 02/22/2016)
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Leukemia

ACUTE LEUKEMIA

ALL

  • No studies at this time

AML

  • Connect® MDS/AML Disease Registry (Celgene NCI-2015-01815)
  • ECOG-ACRIN EA9131: Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
  • M16-043 (Abbive): A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
  • SWOG S1612: A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older (LEAP: Less-Intense AML Platform Trial) (Suspended 10/22/2018)

CHRONIC LEUKEMIA

  • A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
  • EA9161: A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger (< 70) Patients with Chronic Lymphocytic Leukemia (CLL)

Lung Cancer

NON-SMALL CELL

  • Alliance A081105: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
  • Alliance A151216: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (ALCHEMIST Treatment Trial)
  • EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
  • ECOG E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
  • 1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
  • S1800A (A LUNG-MAP Non-Matched Sub-Study) - A Phase II Randomized Study of Ramucirumab Plus Mk3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-LU002: Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

SMALL CELL

  • CALGB 30610: Phase III Randomized Study of Three Different Thoracic Radiotherapy Regimens in Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
  • NRG – LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

MESOTHELIOMA

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Lymphoma

HODGKIN'S

  • ECOG-ACRIN E4412: A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.

NON-HODGKIN'S

  • ECOG-ACRIN EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab alone for patients with Mantle Cell Lymphoma in minimal residual disease- negative first complete remission
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PrE0404: Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
  • PrECOG PrE0403: Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma as Front Line Therapy
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma- Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in treating patients with relapsed or refractory grad I-IIIa Follicular Lymphoma

Melanoma

  • ECOG EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab +Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib +Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
  • ECOG EA6141: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (SUSPENDED 6/23/2017)
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • SWOG S1616: A Phase II Randomized Study of Nivolumab
    (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1Agent.

Multiple Myeloma

  • Alliance A061202: Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
  • ECOG-ACRIN EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering (DETER-SMM)
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Myelodysplastic Syndrome

Pediatric Oncology

For more information regarding our pediatric trials, please contact:

Kaitlin Chambers, CCRC
(608)775-1826
krchambe@gundersenhealth.org

Prevention/Symptom Management

  • DCP-001: Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
  • WF-30917CD: A Stepped-Care Telehealth Approach To Treat Distress In Rural Cancer Survivors

Sarcoma

  • No trials currently available.

Screenings

  • EA1151 TMIST: Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

If you are interested in getting additional information on a research study, please contact:

Lori Meyer, RN, OCN, CCRC
(608) 775-2579 or (800) 362-9567, ext. 52579
lameyer@gundersenhealth.org

Christine Roraff, RN
(608) 775-7001 or (800) 362-9567, ext. 57001
cmroraff@gundersenhealth.org

Jonean Thorsen, RN
(608) 775-7001 or (800) 362-9567, ext. 57001
jethorse@gundersenhealth.org

Love + Medicine

Every day, Gundersen Health System staff deliver great medicine plus a little something extra—we call it Love + Medicine.

Share Your Story